Cowen Maintains Buy on Axsome Therapeutics (AXSM) Feb 2026
AXSM analyst rating: Cowen & Co. maintained a Buy on Axsome Therapeutics, Inc. (AXSM) on February 23, 2026. Cowen also raised its price target to $215 from $195, a move flagged in The Fly on the same day. The update followed the company’s Q4 2025 earnings call and coincided with a 7.3% move in the stock, equaling $12.67 since the change.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
